RT Journal Article
T1 Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
A1 Vega-Garcia, Nerea
A1 Perez-Jaume, Sara
A1 Esperanza-Cebollada, Elena
A1 Vicente-Garces, Clara
A1 Torrebadell, Montserrat
A1 Jimenez-Velasco, Antonio
A1 Ortega, Margarita
A1 Llop, Marta
A1 Abad, Lorea
A1 Vagace, Jose Manuel
A1 Minguela, Alfredo
A1 Pratcorona, Marta
A1 Sanchez-Garcia, Joaquin
A1 Garcia-Calderon, Clara B
A1 Gomez-Casares, Maria Teresa
A1 Martin-Clavero, Estela
A1 Escudero, Adela
A1 Riñon-Martinez-Gallo, Marta
A1 Muñoz, Luz
A1 Velasco, Maria Rosario
A1 Garcia-Morin, Marina
A1 Catala, Albert
A1 Pascual, Antonia
A1 Velasco, Pablo
A1 Fernandez, Jose Mª
A1 Lassaletta, Alvaro
A1 Fuster, Jose Luis
A1 Badell, Isabel
A1 Molinos-Quintana, Agueda
A1 Molines, Antonio
A1 Guerra-Garcia, Pilar
A1 Perez-Martinez, Antonio
A1 Garcia-Abos, Miriam
A1 Robles-Ortiz, Reyes
A1 Pisa, Sandra
A1 Adan, Rosa
A1 Diaz-de-Heredia, Cristina
A1 Dapena, Jose Luis
A1 Rives, Susana
A1 Ramirez-Orellana, Manuel
A1 Camos, Mireia
K1 NOTCH1
K1 T-cell acute lymphoblastic leukemia
K1 Flow cytometry
K1 Measurable (minimal) residual disease
K1 Oncogenetics
K1 Pediatrics
K1 Risk-factors
AB Robust and applicable risk-stratifying genetic factors at diagnosis in pediatric T-cell acute lymphoblastic leukemia (T-ALL) are still lacking, and most protocols rely on measurable residual disease (MRD) assessment. In our study, we aimed to analyze the impact of NOTCH1, FBXW7, PTEN, and RAS mutations, the measurable residual disease (MRD) levels assessed by flow cytometry (FCM-MRD) and other reported risk factors in a Spanish cohort of pediatric T-ALL patients. We included 199 patients treated with SEHOP and PETHEMA consecutive protocols from 1998 to 2019. We observed a better outcome of patients included in the newest SEHOP-PETHEMA-2013 protocol compared to the previous SHOP-2005 cohort. FCM-MRD significantly predicted outcome in both protocols, but the impact at early and late time points differed between protocols. The impact of FCM-MRD at late time points was more evident in SEHOP-PETHEMA 2013, whereas in SHOP-2005 FCM-MRD was predictive of outcome at early time points. Genetics impact was different in SHOP-2005 and SEHOP-PETHEMA-2013 cohorts: NOTCH1 mutations impacted on overall survival only in the SEHOP-PETHEMA-2013 cohort, whereas homozygous deletions of CDKN2A/B had a significantly higher CIR in SHOP-2005 patients. We applied the clinical classification combining oncogenetics, WBC count and MRD levels at the end of induction as previously reported by the FRALLE group. Using this score, we identified different subgroups of patients with statistically different outcome in both Spanish cohorts. In SHOP-2005, the FRALLE classifier identified a subgroup of high-risk patients with poorer survival. In the newest protocol SEHOP-PETHEMA-2013, a very low-risk group of patients with excellent outcome and no relapses was detected, with borderline significance. Overall, FCM-MRD, WBC count and oncogenetics may refine the risk-stratification, helping to design tailored approaches for pediatric T-ALL patients.
PB Frontiers Research Foundation
SN 2296-2360
YR 2021
FD 2021-02-05
LK http://hdl.handle.net/10668/17213
UL http://hdl.handle.net/10668/17213
LA en
NO Vega-García N, Perez-Jaume S, Esperanza-Cebollada E, Vicente-Garcés C, Torrebadell M, Jiménez-Velasco A, et al. Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment. Front Pediatr. 2021 Feb 5;8:614521
DS RISalud
RD Apr 5, 2025